Mast cell leukemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(One intermediate revision by the same user not shown)
Line 10: Line 10:
*D816V c-''KIT'' mutation is the most frequent mutation, found in more than 80% of adult patients with systemic mastocytosis especially in the aggressive forms with a frequency of more than 95% in mast cell leukemia patients.<ref name="JorisGeorgin-Lavialle2012">{{cite journal|last1=Joris|first1=Magalie|last2=Georgin-Lavialle|first2=Sophie|last3=Chandesris|first3=Marie-Olivia|last4=Lhermitte|first4=Ludovic|last5=Claisse|first5=Jean-François|last6=Canioni|first6=Danielle|last7=Hanssens|first7=Katia|last8=Damaj|first8=Gandhi|last9=Hermine|first9=Olivier|last10=Hamidou|first10=Mohammed|title=Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive|journal=Case Reports in Hematology|volume=2012|year=2012|pages=1–6|issn=2090-6560|doi=10.1155/2012/517546}}</ref>
*D816V c-''KIT'' mutation is the most frequent mutation, found in more than 80% of adult patients with systemic mastocytosis especially in the aggressive forms with a frequency of more than 95% in mast cell leukemia patients.<ref name="JorisGeorgin-Lavialle2012">{{cite journal|last1=Joris|first1=Magalie|last2=Georgin-Lavialle|first2=Sophie|last3=Chandesris|first3=Marie-Olivia|last4=Lhermitte|first4=Ludovic|last5=Claisse|first5=Jean-François|last6=Canioni|first6=Danielle|last7=Hanssens|first7=Katia|last8=Damaj|first8=Gandhi|last9=Hermine|first9=Olivier|last10=Hamidou|first10=Mohammed|title=Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive|journal=Case Reports in Hematology|volume=2012|year=2012|pages=1–6|issn=2090-6560|doi=10.1155/2012/517546}}</ref>
*[[Mutation|Mutations]] in ''SRSF2'', ''ASXL1'' or ''RUNX1'' are founded in mast cell leukemia patient.<ref name="JawharSchwaab2017">{{cite journal|last1=Jawhar|first1=Mohamad|last2=Schwaab|first2=Juliana|last3=Meggendorfer|first3=Manja|last4=Naumann|first4=Nicole|last5=Horny|first5=Hans-Peter|last6=Sotlar|first6=Karl|last7=Haferlach|first7=Torsten|last8=Schmitt|first8=Karla|last9=Fabarius|first9=Alice|last10=Valent|first10=Peter|last11=Hofmann|first11=Wolf-Karsten|last12=Cross|first12=Nicholas C.P.|last13=Metzgeroth|first13=Georgia|last14=Reiter|first14=Andreas|title=The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm|journal=Haematologica|volume=102|issue=6|year=2017|pages=1035–1043|issn=0390-6078|doi=10.3324/haematol.2017.163964}}</ref>
*[[Mutation|Mutations]] in ''SRSF2'', ''ASXL1'' or ''RUNX1'' are founded in mast cell leukemia patient.<ref name="JawharSchwaab2017">{{cite journal|last1=Jawhar|first1=Mohamad|last2=Schwaab|first2=Juliana|last3=Meggendorfer|first3=Manja|last4=Naumann|first4=Nicole|last5=Horny|first5=Hans-Peter|last6=Sotlar|first6=Karl|last7=Haferlach|first7=Torsten|last8=Schmitt|first8=Karla|last9=Fabarius|first9=Alice|last10=Valent|first10=Peter|last11=Hofmann|first11=Wolf-Karsten|last12=Cross|first12=Nicholas C.P.|last13=Metzgeroth|first13=Georgia|last14=Reiter|first14=Andreas|title=The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm|journal=Haematologica|volume=102|issue=6|year=2017|pages=1035–1043|issn=0390-6078|doi=10.3324/haematol.2017.163964}}</ref>
*The majority patients with mast cell leukemai have signs of organ damage.<ref name="JawharSchwaab2017">{{cite journal|last1=Jawhar|first1=Mohamad|last2=Schwaab|first2=Juliana|last3=Meggendorfer|first3=Manja|last4=Naumann|first4=Nicole|last5=Horny|first5=Hans-Peter|last6=Sotlar|first6=Karl|last7=Haferlach|first7=Torsten|last8=Schmitt|first8=Karla|last9=Fabarius|first9=Alice|last10=Valent|first10=Peter|last11=Hofmann|first11=Wolf-Karsten|last12=Cross|first12=Nicholas C.P.|last13=Metzgeroth|first13=Georgia|last14=Reiter|first14=Andreas|title=The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm|journal=Haematologica|volume=102|issue=6|year=2017|pages=1035–1043|issn=0390-6078|doi=10.3324/haematol.2017.163964}}</ref>


==Genetics==
==Genetics==

Latest revision as of 14:33, 23 October 2018

Mast cell leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mast cell leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mast cell leukemia pathophysiology On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mast cell leukemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mast cell leukemia pathophysiology

CDC on Mast cell leukemia pathophysiology

Mast cell leukemia pathophysiology in the news

Blogs on Mast cell leukemia pathophysiology

Directions to Hospitals Treating Mast cell leukemia

Risk calculators and risk factors for Mast cell leukemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2], Sogand Goudarzi, MD [3]

Overview

Genes involved in the pathogenesis of mast cell leukemia include KIT D816V and non-KIT D816V.[1][2][3] There are no characteristic findings of mast cell leukemia on gross pathology.[4] On microscopic histopathological analysis, multifocal sheets and clusters of mast cells in bone marrow sections are findings of mast cell leukemia.[5]

Pathogenesis

  • Mutation of KIT is a hallmark of the mast cell leukemia.
  • Adult-type human mastocytosis is characterized by mutations in c-KIT at codon 816, which cause constitutive activation of KIT kinase.
  • Different classes of activating KIT mutations respond differentially to KIT inhibitors depending on the site and type of mutation.
  • D816V c-KIT mutation is the most frequent mutation, found in more than 80% of adult patients with systemic mastocytosis especially in the aggressive forms with a frequency of more than 95% in mast cell leukemia patients.[1]
  • Mutations in SRSF2, ASXL1 or RUNX1 are founded in mast cell leukemia patient.[6]
  • The majority patients with mast cell leukemai have signs of organ damage.[6]

Genetics

Genes involved in the pathogenesis of mast cell leukemia include:[1][2][3]

  • KIT D816V
  • non-KIT D816V

Associated conditions

Mast cell leukemia may be associated with systemic mastocytosis.[2]

Gross Pathology

There are no characteristic findings of mast cell leukemia on gross pathology. Gross specimens are not seen typically.[4]

Microscopic Pathology

On microscopic histopathological analysis, findings of mast cell leukemia include:[5]

  • Multifocal sheets of mast cells
  • Clusters of mast cells

Gallery

  • Peripheral blood showing mast cell leukemia.[7]

    Peripheral blood showing mast cell leukemia.[7]

Immunohistochemistry

  • Atypical mast cells express multiple surface antigens such as:[1]

References

  1. ↑ 1.0 1.1 1.2 1.3 Joris, Magalie; Georgin-Lavialle, Sophie; Chandesris, Marie-Olivia; Lhermitte, Ludovic; Claisse, Jean-François; Canioni, Danielle; Hanssens, Katia; Damaj, Gandhi; Hermine, Olivier; Hamidou, Mohammed (2012). "Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive". Case Reports in Hematology. 2012: 1–6. doi:10.1155/2012/517546. ISSN 2090-6560.
  2. ↑ 2.0 2.1 2.2 Georgin-Lavialle, S.; Lhermitte, L.; Dubreuil, P.; Chandesris, M.-O.; Hermine, O.; Damaj, G. (2012). "Mast cell leukemia". Blood. 121 (8): 1285–1295. doi:10.1182/blood-2012-07-442400. ISSN 0006-4971.
  3. ↑ 3.0 3.1 Kristensen, Thomas; Vestergaard, Hanne; Møller, Michael Boe (2011). "Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay". The Journal of Molecular Diagnostics. 13 (2): 180–188. doi:10.1016/j.jmoldx.2010.10.004. ISSN 1525-1578.
  4. ↑ 4.0 4.1 Horvai AE, Link TM. Bone and Soft Tissue Pathology. Elsevier Health Sciences (2012). http://books.google.com?id=p2DV6VWdXx8C. Accessed on November 30, 2015.
  5. ↑ 5.0 5.1 Valent, P.; Sotlar, K.; Sperr, W. R.; Escribano, L.; Yavuz, S.; Reiter, A.; George, T. I.; Kluin-Nelemans, H. C.; Hermine, O.; Butterfield, J. H.; Hagglund, H.; Ustun, C.; Hornick, J. L.; Triggiani, M.; Radia, D.; Akin, C.; Hartmann, K.; Gotlib, J.; Schwartz, L. B.; Verstovsek, S.; Orfao, A.; Metcalfe, D. D.; Arock, M.; Horny, H.- P. (2014). "Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal". Annals of Oncology. 25 (9): 1691–1700. doi:10.1093/annonc/mdu047. ISSN 0923-7534.
  6. ↑ 6.0 6.1 Jawhar, Mohamad; Schwaab, Juliana; Meggendorfer, Manja; Naumann, Nicole; Horny, Hans-Peter; Sotlar, Karl; Haferlach, Torsten; Schmitt, Karla; Fabarius, Alice; Valent, Peter; Hofmann, Wolf-Karsten; Cross, Nicholas C.P.; Metzgeroth, Georgia; Reiter, Andreas (2017). "The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm". Haematologica. 102 (6): 1035–1043. doi:10.3324/haematol.2017.163964. ISSN 0390-6078.
  7. ↑ Image of peripheral blood smear of acute mast cell leukemia. Wikipedia (2015). https://en.wikipedia.org/wiki/Mast_cell_leukemia. Accessed on December 2, 2015

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Mast_cell_leukemia_pathophysiology&oldid=1499300"